Three-way Complex Variant Translocation Involving Long Arm of Chromosome 1 in a Chronic Myeloid Leukemia Patient

Syeda Ambareen Zehra a, Mamona Mushtaq b, Azfar Ahmed a and Neelum Mansoor c*

a Cytogenetics Section, Department of Hematology, Indus Hospital and Health Network, Karachi, Pakistan.
b Indus Hospital Research Centre, Indus Hospital and Health Network, Karachi, Pakistan.
c Department of Hematology and Blood Centre, Indus Hospital and Health Network, Karachi, Pakistan.

Authors’ contributions
This work was carried out in collaboration among all authors. Authors SAZ and AA identified the case, analyzed and interpret data, author MM did literature search, prepared the draft and revised it where required, author NM worked on concept and design and critically reviewed the content. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/IBRR/2022/v13i330177

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/86843

Received 25 February 2022
Accepted 04 May 2022
Published 07 May 2022

ABSTRACT

Clinical presentation of chronic myeloid leukemia (CML) with classic translocation is similar to those with variant translocations. However, the disease course, outcome and prognosis differs to a large extent. Therefore, it is important to identify and report variant cytogenetic findings. The case is being reported to improve awareness regarding such cases.

Case Presentation: Herein we present a case study of 55-year-old male who presented with abdominal pain and fever. The initial complete blood count showed hyperleukocytosis with features suggestive of chronic myeloproliferative leukemia (CML). Bone marrow biopsy and cytogenetic studies were performed for confirmation. Cytogenetic analysis showed presence of complex, three-way (1;9;22)(q12;q34;q11.2) translocation involving chromosomes 1, 9 and 22. The Fluorescence in situ hybridization (FISH) studies further confirmed BCR-ABL fusion gene and its atypical pattern was in concordance with aberrations observed in karyotype. The variant translocation we reported herein is unique and rarely reported in literature.

*Corresponding author: E-mail: neelum.mansoor@tih.org.pk;
Discussion: We presented a complex variant case of three-way translocation with characteristic hematological and immunophenotypic findings of CML in chronic phase. To the best of our knowledge, only few cases have been documented so far involving such complex translocation. The initial response to cytoreduction was encouraging while imatinib response has to be followed in present case. Conclusion: It is important to highlight the variant translocations since such findings may influence the disease course hence play a significant role to predict outcome.

Keywords: Three-way variant translocation; CML; FISH; cytogenetics.

1. INTRODUCTION

Chronic myeloid leukemia (CML) is a neoplasm of hematopoietic stem cells. It is characterized by the presence of Philadelphia (Ph) chromosome resulting from the reciprocal translocation between chromosome 9 and 22 [1]. Presence of Philadelphia chromosome is a hallmark of CML and its correlation with FISH signal patterns is crucial to identify variant translocations or additional chromosome aberrations. This translocation events triggers the formation of BCR-ABL1 fusion gene [2]. The resultant proteins possess a constitutive tyrosine kinase activity, thus playing a pivotal role in phosphorylation. Thereby, it affects multitude of the intracellular signaling events regulating the cell processes for instance NF-Kb, Jak-Stat, Ras, PI3K/AKT, consequently malignant transformation [3]. Besides classical CML translocation i.e. t(9;22)(q34;q11), variant translocation involving other chromosomes have been reported in 5-10% of the CML patients [4]. These variant translocations have a significant impact on outcome and are known to be associated with adverse prognosis.

2. CASE PRESENTATION

A 55 years’ male presented with complaints of abdominal pain, facial and pedal swelling associated with fever for last two months. There is also history of undocumented weight loss (>15 kg) in last 3-4 months. On examination, he has cervical lymphadenopathy and splenomegaly. Ultrasound abdomen showed enlarged spleen. Initial CBC revealed Hb: 5.8gm/dl, TLC: 158x10E9/L and platelet: 168x10E9/L. Blood film showed hyperleukocytosis, leukoerythroblastic blood picture, occasional blasts and absolute basophilia. Bone marrow biopsy is performed to ascertain the phase of disease. Spiculated and cellular bone marrow aspirate exhibit trilineage hematopoeisis along with myeloid hyperplasia. Immunohistochemistry performed on bone marrow biopsy showed sprinkling positivity for CD34 and CD117 thus excluding any foci of blasts. Reticulin stain showed grade I fibrosis. Hence the case was concluded as CML in chronic phase. At the same time, patient’s sample was received for cytogenetic workup including conventional karyotyping and interphase fluorescence in situ hybridization (FISH).

For Conventional cytogenetic analysis bone marrow culture (24 hours) was setup. After unstimulated culturing metaphase was arrested by colcemid, then treated with hypotonic solution and followed by fixation using preformed fixative (Methanol:Glacial acetic acid). After fixation slides were made and GTG banding was performed. By using Cytovision software for analysis, total 20 GTG banded metaphase cells were analyzed. The karyotype revealed an abnormal male chromosome complement with a complex, three way (1;9;22) translocation between long arms of chromosomes 1, 9 and 22 resulting in Ph chromosome in all cells [Fig. 1]. FISH dual color dual fusion probe was used to detect the presence of BCR-ABL fusion in 200 interphase nuclei cells. FISH revealed that 98% of the cells analyzed were positive for the BCR-ABL fusion however the pattern was atypical i.e. showing single fusion instead of dual fusion which was concordant with the findings identified in karyotype [Fig. 2]. Ideally, the findings of interphase FISH should be confirmed by metaphase FISH to locate the BCR-ABL fusion but it could not be performed. This is the limitation of this case study as currently we do not have validated metaphase FISH in our section. Initial response of this patient to conventional therapy was encouraging however a long follow up is required to comment on clinical outcome with this variant cytogenetic finding.

3. DISCUSSION

A positive balanced translocation for Philadelphia (Ph) chromosome is well
established in majority i.e. ~95% of the CML patients. Nevertheless, complex and variant translocations have been shown by a small fraction 5–8% of all CML patients, due to the involvement of one or more chromosome, along with 9 and 22. The most common underlying molecular event in classical variant translocations is the production of the BCR-ABL fusion gene possessing kinase activity. BCR-ABL leads to auto-phosphorylation and uncontrolled signaling to oncprotiens resulting in myeloid proliferation [2,5].

The pathogenesis underlying the complex karyotypic translocations is poorly understood however, the random aberrations in general are thought to result from the genome instability. In particular, two sustainable mechanisms are proposed by Mkrtchyan et al (2008); the single event rearrangement resulting from the instantaneous breaks in chromosome followed by mismatched joining, or it may involve multiple translocation events following a multi-step mechanism involving more chromosomes in addition to standard 9 and 22 chromosomes [6,7].

Fig. 1. Cytogenetic analysis revealing a variant three-way translocation 46,XX,t (1;9;22)(q12;q34;q11.2). Arrowheads highlight the derivative chromosomes.

Fig. 2. Dual color dual fusion probe depicting atypical pattern (1Green 1Red 1Fusion) of BCR-ABL1 fusion by interphase FISH (Green=BCR on chromosome 9, Red=ABL on chromosome 22)
Three-way Ph chromosome variant in CML has been described in past, derived from the participation of a third chromosome with the classical translocation. A large study pertaining to additional cytogenetic aberrations in CML revealed three way translocations at the time of diagnosis. Of the 1151 patients studied by Fabarius et al (2011), variant translocation t(v;22) was identified in 69 (6.0%) cases, where 60 (87.0%) of the patients harbored three-way variant translocation i.e. the involvement of one additional chromosome [8]. In particular, ~14 variant translocations involving chromosome 4 [t(4q;9;22)] have been reported so far with 4p16 and 4q25 being the major breakpoints. Tori and colleague recently reported unique three-way variant t(4;9;22)(q21;q34;q11.2). According to published literature, these complex variants along with additional cytogenetic aberrations have negative impact on clinical outcome of CML patients [9].

Similarly, translocation involving chromosome 3 has also been reported in some cases. Li and colleagues reported three-way translocation t(3;9;22;p21;q34;q11) in a 42-year-old male. They suggested identified translocation to be associated with poor prognosis in CML patients if treated with imatinib [10]. Involvement of chromosomes 7 and 17 is also documented in literature in cases of three way translocations [11,12].

Herein, we presented a complex variant case of Ph chromosome 46,XX,t(1;9;22)(q12;q34;q11.2) with characteristic hematological and immunophenotypic findings of CML in chronic phase [13]. To the best of our knowledge, only few cases have been documented so far involving such complex translocation. In past an unusual translocation involving chromosomes 1, 9, and 22 with the breakpoints at bands lp22, 9q34, and 22q11, respectively has been reported by Adhvaryu et al (1988) [14]. Further, a balanced three-way translocation t(1;9;22) (q25;q34;q11.2) associated with poor prognosis has also been documented elsewhere [15]. Similar three-way translocation though with different breakpoints, t(1;9;22)(p36;q34;q11) has been reported in a 24-year-old female in the chronic phase of CML. Whereas, when monitored suboptimal response indicative of poor prognosis towards imatinib mesylate (BCR-ABL protein tyrosine kinase inhibitor) was observed. Whereas, in present case it is too early to comment on outcome as the initial response to cy toreduction was encouraging while imatinib response has to be followed.

4. CONCLUSION

In conclusion, it is important to highlight the variant translocations as these findings may influence the disease course. Moreover, early identification of additional cytogenetic aberrations are decisive in terms of management and consequently play a significant role in prediction of prognosis.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


© 2022 Zehra et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/86843

20